Central ocular motor disorders, including gaze palsy and nystagmus

Leigh RJ, Zee D (2006) The neurology of eye movements. Oxford University Press, Oxford

Strupp M, Hufner K, Sandmann R, Zwergal A, Dieterich M, Jahn K, Brandt T (2011) Central oculomotor disturbances and nystagmus: a window into the brainstem and cerebellum. Dtsch Arztebl Int 108:197–204

Brandt T, Dieterich M, Strupp M (2013) Vertigo and dizziness—common complaints, 2nd edn. Springer, London

Cnyrim CD, Newman-Toker D, Karch C, Brandt T, Strupp M (2008) Bedside differentiation of vestibular neuritis from central “vestibular pseudoneuritis”. J Neurol Neurosurg Psychiatry 79:458–460

Kattah JC, Talkad AV, Wang DZ, Hsieh YH, Newman-Toker DE (2009) HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke 40:3504–3510

Buttner-Ennever JA (2008) Mapping the oculomotor system. Prog Brain Res 171:3–11

Brandt T, Dieterich M (1987) Pathological eye-head coordination in roll: tonic ocular tilt reaction in mesencephalic and medullary lesions. Brain 110:649–666

Dieterich M, Brandt T (1993) Ocular torsion and perceived vertical in oculomotor, trochlear and abducens nerve palsies. Brain 116:1095–1104

Dieterich M, Brandt T (1992) Wallenberg’s syndrome: lateropulsion, cyclorotation and subjective visual vertical in thirty-six patients. Ann Neurol 31:399–408

Dieterich M, Brandt T (1993) Ocular torsion and tilt of subjective visual vertical are sensitive brainstem signs. Ann Neurol 33:292–299

Halmagyi GM, Brandt T, Dieterich M, Curthoys IS, Stark RJ, Hoyt WF (1990) Tonic contraversive ocular tilt reaction due to unilateral meso-diencephalic lesion. Neurology 40:1503–1509

Brandt T, Dieterich M (1991) Different types of skew deviation. J Neurol Neurosurg Psychiatry 54:549–550

Ko MW, Dalmau J, Galetta SL (2008) Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 28:58–68

Shallo-Hoffmann J, Schwarze H, Simonsz HJ, Muhlendyck H (1990) A reexamination of end-point and rebound nystagmus in normals. Invest Ophthalmol Vis Sci 31:388–392

Marti S, Straumann D, Glasauer S (2005) The origin of downbeat nystagmus: an asymmetry in the distribution of on-directions of vertical gaze-velocity purkinje cells. Ann N Y Acad Sci 1039:548–553

Salsano E, Umeh C, Rufa A, Pareyson D, Zee DS (2012) Vertical supranuclear gaze palsy in Niemann–Pick type C disease. Neurol Sci 33:1225–1232

Halmagyi GM, Curthoys IS (1988) A clinical sign of canal paresis. Arch Neurol 45:737–739

Halmagyi GM, Curthoys IS (2000) A clinical sign of canal paresis. Arch Neurol 45:737–739

Bartl K, Lehnen N, Kohlbecher S, Schneider E (2009) Head impulse testing using video-oculography. Ann N Y Acad Sci 1164:331–333

Gauthier GM, Vercher JL (1990) Visual vestibular interaction: vestibulo-ocular reflex suppression with head-fixed target fixation. Exp Brain Res 81:150–160

Chen AL, Riley DE, King SA, Joshi AC, Serra A, Liao K, Cohen ML, Otero-Millan J, Martinez-Conde S, Strupp M, Leigh RJ (2010) The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis. Front Neurol 1:147

Vanier MT (2013) Niemann–Pick diseases. Handb Clin Neurol 113:1717–1721

Garver WS, Francis GA, Jelinek D, Shepherd G, Flynn J, Castro G, Walsh VC, Coppock DL, Pettit KM, Heidenreich RA, Meaney FJ (2007) The National Niemann–Pick C1 disease database: report of clinical features and health problems. Am J Med Genet A 143A:1204–1211

King G, Sharom FJ (2012) Proteins that bind and move lipids: MsbA and NPC1. Crit Rev Biochem Mol Biol 47:75–95

Poirier S, Mayer G, Murphy SR, Garver WS, Chang TY, Schu P, Seidah NG (2013) The cytosolic adaptor AP-1A is essential for the trafficking and function of Niemann–Pick type C proteins. Traffic 14:458–469

Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, Sedel F (2007) The adult form of Niemann–Pick disease type C. Brain 130:120–133

Abel LA, Walterfang M, Fietz M, Bowman EA, Velakoulis D (2009) Saccades in adult Niemann–Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology 72:1083–1086

Solomon D, Winkelman AC, Zee DS, Gray L, Buttner-Ennever J (2005) Niemann–Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology. Ann N Y Acad Sci 1039:436–445

Walterfang M, Macfarlane MD, Looi JC, Abel L, Bowman E, Fahey MC, Desmond P, Velakoulis D (2012) Pontine-to-midbrain ratio indexes ocular-motor function and illness stage in adult Niemann–Pick disease type C. Eur J Neurol 19:462–467

Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, Vanier MT, Pineda M (2013) Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 8:12

Klunemann HH, Santosh PJ, Sedel F (2012) Treatable metabolic psychoses that go undetected: what Niemann–Pick type C can teach us. Int J Psychiatry Clin Pract 16:162–169

Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F (2012) Recommendations for the diagnosis and management of Niemann–Pick disease type C: an update. Mol Genet Metab 106:330–344

Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann–Pick C disease: a randomised controlled study. Lancet Neurol 6:765–772

Pineda M, Wraith JE, Mengel E, Sedel F, Hwu WL, Rohrbach M, Bembi B, Walterfang M, Korenke GC, Marquardt T, Luzy C, Giorgino R, Patterson MC (2009) Miglustat in patients with Niemann–Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 98:243–249

Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topcu M, Vanier MT, Widner H, Wijburg FA, Patterson MC (2009) Recommendations on the diagnosis and management of Niemann–Pick disease type C. Mol Genet Metab 98:152–165

Hollak CE (2012) An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid 7:15–20

Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R, FitzGibbon EJ (2011) The saccadic and neurological deficits in type 3 Gaucher disease. PLoS One 6:e22410

Desnick RJ (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27:385–410

Schiffmann R, FitzGibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M, Vellodi A (2008) Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64:514–522

Cox TM (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11:1169–1181

Doneda D, Netto CB, Moulin CC, Schwartz IV (2013) Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond) 10:34

Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH (2005) Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 7:119–123

Grosso S, Farnetani MA, Berardi R, Margollicci M, Galluzzi P, Vivarelli R, Morgese G, Ballestri P (2003) GM2 gangliosidosis variant B1 neuroradiological findings. J Neurol 250:17–21

Walterfang M, Bonnot O, Mocellin R, Velakoulis D (2013) The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis 36:687–702

Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S, Peleg L, Lerman-Sagie T, Zimran A, Elstein D, Navon R, Stern N, Valevski A (2011) Pyrimethamine increases beta-hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol Genet Metab 102:356–363

Salman MS, Ikeda KM (2013) The syndrome of infantile-onset saccade initiation delay. Can J Neurol Sci 40:235–240

Harris CM, Shawkat F, Russell-Eggitt I, Wilson J, Taylor D (1996) Intermittent horizontal saccade failure (‘ocular motor apraxia’) in children. Br J Ophthalmol 80:151–158

Le Ber I, Moreira MC, Rivaud-Pechoux S, Chamayou C, Ochsner F, Kuntzer T, Tardieu M, Said G, Habert MO, Demarquay G, Tannier C, Beis JM, Brice A, Koenig M, Durr A (2003) Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain 126:2761–2772

Le Ber I, Bouslam N, Rivaud-Pechoux S, Guimaraes J, Benomar A, Chamayou C, Goizet C, Moreira MC, Klur S, Yahyaoui M, Agid Y, Koenig M, Stevanin G, Brice A, Durr A (2004) Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. Brain 127:759–767

Panouilleres M, Frismand S, Sillan O, Urquizar C, Vighetto A, Pelisson D, Tilikete C (2013) Saccades and eye-head coordination in ataxia with oculomotor apraxia type 2. Cerebellum 12:557–567

Durr A (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9:885–894

Klockgether T, Paulson H (2011) Milestones in ataxia. Mov Disord 26:1134–1141

Gispert S, Twells R, Orozco G, Brice A, Weber J, Heredero L, Scheufler K, Riley B, Allotey R, Nothers C (1993) Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet 4:295–299

Geiner S, Horn AK, Wadia NH, Sakai H, Buttner-Ennever JA (2008) The neuroanatomical basis of slow saccades in spinocerebellar ataxia type 2 (Wadia-subtype). Prog Brain Res 171:575–581

Kim JS, Kim JS, Youn J, Seo DW, Jeong Y, Kang JH, Park JH, Cho JW (2013) Ocular motor characteristics of different subtypes of spinocerebellar ataxia: distinguishing features. Mov Disord 28:1271–1277

Rub U, Brunt ER, Seidel K, Gierga K, Mooy CM, Kettner M, Van Broeckhoven C, Bechmann I, La Spada AR, Schols L, den Dunnen W, de Vos RA, Deller T (2008) Spinocerebellar ataxia type 7 (SCA7): widespread brain damage in an adult-onset patient with progressive visual impairments in comparison with an adult-onset patient without visual impairments. Neuropathol Appl Neurobiol 34:155–168

Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K (2013) Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series. J Neurol 260:2556–2561

Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ (2011) Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 258:1207–1222

Aure K, de Ogier BH, Laforet P, Jardel C, Eymard B, Lombes A (2007) Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: can we predict progression? Brain 130:1516–1524

DeBrosse S, Ubogu EE, Yaniglos S, Hassan MO, Leigh RJ (2009) Dynamic properties of eye movements in mitochondrial chronic progressive external ophthalmoplegia. Eye (Lond) 23:382–388

Ritchie AE, Griffiths PG, Chinnery PF, Davidson AW (2010) Eye movement recordings to investigate a supranuclear component in chronic progressive external ophthalmoplegia: a cross-sectional study. Br J Ophthalmol 94:1165–1168

Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, Nakase H, Bonilla E, Werneck LC, Servidei S (1989) Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 320:1293–1299

Compain C, Sacre K, Puechal X, Klein I, Vital-Durand D, Houeto JL, De BT, Raoult D, Papo T (2013) Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore) 92:324–330

Schwartz MA, Selhorst JB, Ochs AL, Beck RW, Campbell WW, Harris JK, Waters B, Velasco ME (1986) Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple’s disease. Ann Neurol 20:677–683

Louis ED (2003) Whipple disease. Curr Neurol Neurosci Rep 3:470–475

Wagner JN, Glaser M, Brandt T, Strupp M (2008) Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 79:672–677

Strupp M, Kremmyda O, Brandt T (2013) Pharmacotherapy of vestibular disorders and nystagmus. Semin Neurol 33:286–296

Strupp M, Schuler O, Krafczyk S, Jahn K, Schautzer F, Buttner U, Brandt T (2003) Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 61:165–170

Kalla R, Deutschlander A, Hufner K, Stephan T, Jahn K, Glasauer S, Brandt T, Strupp M (2006) Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology 66:281–283

Claassen J, Spiegel R, Kalla R, Faldon M, Kennard C, Danchaivijitr C, Bardins S, Rettinger N, Schneider E, Brandt T, Jahn K, Teufel J, Strupp M, Bronstein A (2013) A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 84:1392–1399

Kalla R, Glasauer S, Buttner U, Brandt T, Strupp M (2007) 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 130:2441–2451

Etzion Y, Grossman Y (2001) Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 139:419–425

Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268

Dieterich M, Straube A, Brandt T, Paulus W, Buttner U (1991) The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 54:627–632

Glasauer S, Kalla R, Buttner U, Strupp M, Brandt T (2005) 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J Neurol Neurosurg Psychiatry 76:451–453